Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)
Status:
Enrolling by invitation
Trial end date:
2024-02-28
Target enrollment:
Participant gender:
Summary
This will be a Phase II, open-label, single-arm, multicenter study of the efficacy and safety
of osimertinib (80 mg orally once daily) in patients with LM associated with EGFRm+ NSCLC.